Subscribe

Grand Pharmaceutical Group Limited (0512.HK)

HKD5.26 +0.06 (+1.15%)
HK HKSE Healthcare Medical - Pharmaceuticals
Address The Center
Hong Kong, HK
CEO Chao Zhou
Website grandpharm.com
IPO 2004-05-11
ISIN BMG210A71016

Explore sections of this company profile

Description

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD5.26 +0.06 (+1.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.67
Float Shares
1.26B
Free Float %
35.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.38% -2.96% -15.76% -33.08% -36.25% -33.25% -39.35% +4.38% -35.23% +1,762.85% +2,200.97%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
5.26
DCF (Unlevered) 11.35 +115.9%
DCF (Levered) 7.68 +46.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 5 +1
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.15
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +5.5% Q4'25: +36.0% (vs Q4'23)
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    -50.0% Q4'25: -91.5% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +8.2% Q4'25: +15.7% (vs Q4'23)
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +14.4% ★ Q4'25: +9.2% (vs Q4'23)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +7.4% ★ Q4'25: +6.9% (vs Q4'23)
  • ✓
    Share dilution Medical - Pharmaceuticals: +0.0%
    +0.0% Q4'25: +0.0% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    2.04× Q4'25: 1.38× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.74) × ERP
WACC = 80% × Ke + 20% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 11.39 Current price: 5.26
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
4 Rev. Ana.
5 EPS Ana. 		Dec 2027
4 Rev. Ana.
4 EPS Ana. 		Dec 2028
2 Rev. Ana.
3 EPS Ana.
Revenue
4.77B
est: 4.26B (+12.1%)
5.96B
est: 6.79B (-12.3%)
6.59B
est: 7.18B (-8.2%)
6.35B
est: 7.38B (-13.9%)
8.60B
est: 8.51B (+1.0%)
9.56B
est: 10.43B (-8.3%)
10.53B
est: 10.62B (-0.8%)
11.64B
est: 11.35B (+2.6%)
12.28B
est: 12.35B (-0.5%)
13.66B
13.43B – 14.01B
+10.6% YoY
14.92B
14.49B – 15.35B
+9.2% YoY
16.12B
15.75B – 16.57B
+8.1% YoY
EBITDA
976.63M
est: 1.39B (-29.9%)
1.32B
est: 2.22B (-40.5%)
1.86B
est: 2.35B (-20.7%)
2.41B
est: 2.42B (-0.1%)
3.10B
est: 2.79B (+11.4%)
3.09B
est: 3.42B (-9.5%)
2.97B
est: 3.48B (-14.7%)
3.39B
est: 3.28B (+3.3%)
2.31B
est: 3.57B (-35.3%)
3.95B
3.88B – 4.05B
+10.6% YoY
4.31B
4.19B – 4.44B
+9.2% YoY
4.66B
4.55B – 4.79B
+8.1% YoY
EBIT
733.37M
est: 1.22B (-39.8%)
1.09B
est: 1.94B (-44.1%)
1.50B
est: 2.06B (-26.9%)
2.13B
est: 2.11B (+0.8%)
2.76B
est: 2.44B (+13.5%)
2.70B
est: 2.99B (-9.6%)
2.57B
est: 3.04B (-15.3%)
2.88B
est: 2.81B (+2.5%)
1.77B
est: 3.06B (-42.3%)
3.39B
3.33B – 3.47B
+10.6% YoY
3.70B
3.59B – 3.81B
+9.2% YoY
4.00B
3.91B – 4.11B
+8.1% YoY
Net Income
460.81M
est: 522.44M (-11.8%)
712.67M
est: 945.49M (-24.6%)
1.15B
est: 1.19B (-3.3%)
1.79B
est: 1.36B (+31.4%)
2.40B
est: 2.10B (+14.3%)
2.08B
est: 1.78B (+16.7%)
1.88B
est: 1.86B (+0.9%)
2.47B
est: 2.10B (+17.5%)
1.24B
est: 2.07B (-39.9%)
1.87B
1.44B – 2.23B
-9.6% YoY
2.09B
1.67B – 2.51B
+11.9% YoY
2.24B
2.17B – 2.32B
+7.3% YoY
SGA
1.87B
est: 1.57B (+18.5%)
2.31B
est: 2.51B (-8.0%)
2.85B
est: 2.66B (+7.2%)
2.55B
est: 2.73B (-6.7%)
3.31B
est: 3.15B (+5.0%)
3.40B
est: 3.86B (-12.0%)
3.29B
est: 3.93B (-16.3%)
4.62B
est: 4.25B (+8.8%)
5.20B
est: 4.62B (+12.4%)
5.11B
5.03B – 5.24B
+10.6% YoY
5.59B
5.43B – 5.75B
+9.2% YoY
6.04B
5.90B – 6.20B
+8.1% YoY
EPS
0.21
est: 0.15 (+40.8%)
0.27
est: 0.27 (+0.0%)
0.35
est: 0.34 (+2.9%)
0.52
est: 0.39 (+33.5%)
0.68
est: 0.60 (+13.3%)
0.59
est: 0.51 (+15.9%)
0.54
est: 0.53 (+1.5%)
0.70
est: 0.60 (+16.7%)
0.35
est: 0.59 (-40.7%)
0.53
0.41 – 0.64
-9.6% YoY
0.60
0.48 – 0.72
+11.9% YoY
0.64
0.62 – 0.66
+7.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-28 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-27 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-26 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-22 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-21 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-20 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-19 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-18 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-15 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-14 B+ 3/5 4/5 4/5 4/5 2/5 2/5 3/5
2026-05-13 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-12 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-11 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-08 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-07 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-06 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-05 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-04 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-30 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-29 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-28 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-27 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-24 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-23 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-22 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
3.60B
OE per share TTM
1.03
Owner's Yield
19.62%
Maintenance CapEx ratio
204.91%
Maint CapEx / Avg PPE
41.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 58 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI China Small-Cap ETF ECNS 0.46% 298.6K 0.59%
2 WisdomTree China ex-State-Owned Enterprises Fund CXSE 0.09% 469.6K 0.32%
3 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.08% 100.3K 0.42%
4 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.07% 48.2K 0.74%
5 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.06% 338.8K 0.55%
6 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.05% 164.9K 0.74%
7 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.04% 162.7K 0.72%
8 Schwab Fundamental International Small Company Index ETF FNDC 0.02% 692.2K 0.39%
9 Dimensional - Emerging Markets Value ETF DFEV 0.02% 364.9K 0.46%
10 Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L 0.02% 42.3K 0.35%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
140.1K
Shares Outstanding
3.50B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chao Zhou Chief Executive Officer & Executive Director 4M male
Weikun Tang Executive Chairman 3M —
Chit Yee Lam Executive Director 50.0K female
Guang Yang Executive Director 50.0K male
Xiaofeng Shi Chairman of Grand Pharm (China) — male
Xiaojie Chen Vice President — —
Liu Hu Investor Relations Director — —
Tin Chang Foo HKICPA Company Secretary — male
Tin Chung Foo HKICPA Company Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals